GlassScriptPhysician profile
Randi H Hatton
NPI 1578153391
$1,995.02
in general payments reported to CMS, 2019-2025
30 companies · $646 in 2025
The $646 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.78 · 2022: $17.34 · 2023: $237 · 2024: $1,017 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.26 | 2021-2025 | |
| Lilly USA, LLC | $207.90 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $166.42 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.27 | 2023-2024 | Trulance |
| Novo Nordisk INC | $125.04 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Corium, LLC | $93.68 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $80.21 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $73.10 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $62.31 | 2025 | Myfembree |
| Exact Sciences Corporation | $60.88 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $55.09 | 2024-2025 | Trintellix |
| Amgen INC. | $49.15 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.60 | 2023-2025 | Jardiance |
| Tris Pharma INC | $42.75 | 2025 | Dyanavel Xr |
| Ibsa Pharma INC. | $41.12 | 2024 | Tirosint, Licart |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $37.97 | 2024-2025 | Ibsrela |
| Becton, Dickinson and Company | $35.77 | 2025 | Hemosphere |
| Axsome Therapeutics, INC. | $34.12 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $31.83 | 2024 | Airsupra |
| Exeltis, USA INC. | $23.80 | 2025 | Slynd |
| Medicure Pharma INC. | $22.83 | 2024 | Zypitamag |
| Dexcom, INC. | $18.65 | 2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $18.07 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.99 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $17.99 | 2025 | Zurzuvae |
| Allergan, INC. | $17.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2025 | |
| Antares Pharma, INC. | $17.40 | 2024 | Xyosted |
| Shield Therapeutics INC | $17.18 | 2025 | |
| Organon LLC | $15.30 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Hatton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.